Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
GLP-1 receptor agon
>>
Phase 1
Welcome,
Profile
Billing
Logout
All trials
Active industry trials
Active owner-sponsored trials
Active trials
Export
Download options
Which format:
PDF
Excel Chart
TSV
Phase
N/A
1
2
3
4
Trials
0
1
2
3
4
5
6
7
8
9
10
LY3493269
/ Eli Lilly
AZD5004
/ AstraZeneca
BI 3006337
/ Boehringer Ingelheim
CM3.1-AC100
/ Boston Scientific
NN9277
/ Novo Nordisk
PF-04856883
/ Pfizer
ZT002
/ Beijing QL Biopharma
NN9423
/ Novo Nordisk
semaglutide once weekly
(NN9904) / Novo Nordisk
14028 injection
(dulaglutide biosimilar) / HEC Pharm
AZD0186
/ AstraZeneca
DR10624
/ Huadong Medicine
GSK2374697
/ GSK
KN056
/ Alphamab
KP405
/ Kariya Pharma
MEDI4166
/ AstraZeneca
NN9925
/ Novo Nordisk
OG2023SC
/ Novo Nordisk
PEGylated oxyntomodulin long acting
(MOD-6031) / OPKO Health
RD12014
(liraglutide biosimilar) / HEC Pharm
RG6640
/ Roche
SHR-1816
/ Jiangsu Hengrui Pharma
XW014
/ Sciwind Biosci
dapagliflozin/semaglutide
(NN9917) / Novo Nordisk
exenatide SR
(DA-3091) / Dong-A
exenatide implant
(NPM-119) / Vivani Medical
exenatide-XTEN
(VRS-859) / Aravive
liraglutide
(4P004) / 4P-Pharma
liraglutide depot
(NN9223) / Novo Nordisk
oxyntomodulin LA
(MOD-6030) / OPKO Health
recombinant exendin-4
(Uni-E4) / Uni-Bio Sci
